AJOVY is available in an autoinjector. Learn more

You had searched for:

There were no results matching the query.

You can also browse the topics below to find what you are looking for.

Patient Profiles


Maura

Anna

Need help answering a question?

Support Services

  1. Download the Prescription and Service Request Form (PSRF)
  2. Fax the completed form to Shared Solutions® at 1-844-257-6127

Patients can call 1-800-887-8100, Monday–Friday, 8 am–6 pm CT.

Anna Episodic migraine patient

  • Anna’s migraine gets in the way of her professional responsibilities

  • She is currently on an oral preventive treatment, but she continues to experience migraine days

  • Anna would like the flexibility to choose a dosing option

" Is AJOVY right for me? "

 

Significantly more migraine-free days with AJOVY vs placebo1

In episodic migraine, a reduction in monthly migraine days was demonstrated during the 12-week period (primary endpoint), with results seen as early as week 11,2

  • Patients with a mean baseline of 8.9 migraine days per month experienced 3.7 fewer migraine days per month, on average, with monthly dosing (vs 2.2 with placebo)1*
  • 47.7% of patients with episodic migraine achieved at least a 50% reduction in monthly average migraine days with monthly dosing vs 27.9% for placebo (secondary endpoints)1*

SEE EFFICACY DATA FOR AJOVY

AJOVY is the only anti-CGRP injection with the option of dosing just 4 times a year

Quarterly dosing option for AJOVY

Only 4 injection days per year with quarterly dosing 675 mg SC

AJOVY can also be administered monthly 225 mg SC

  • Administration at home by a patient or caregiver or in office by a healthcare professional
    • Guidance on proper subcutaneous administration techniques should be provided
  • The most common adverse reaction (≥5% and greater than placebo) were injection-site reactions1

SEE DOSING FOR AJOVY

Study design1-3

AJOVY was evaluated in three phase 3, 12-week, randomized, double-blind, placebo-controlled, parallel-group trials, and a long-term extension study

  • In the HALO Episodic migraine trial, the primary endpoint, for both quarterly and monthly dosing, was the mean change from baseline in the monthly average number of migraine days during the 12-week period

SEE STUDY DESIGNS *P<0.001.1 Patients with a mean baseline of 9.2 migraine days per month experienced 3.4 fewer migraine days per month, on average, with quarterly dosing vs 2.2 days with placebo, P<0.001.1 44.4% of patients with episodic migraine achieved at least a 50% reduction in monthly average migraine days with quarterly dosing vs 27.9% for placebo, P<0.001.1

Suggestions to explore next

Continue to AJOVY clinical trial results page

AJOVY helped significantly reduce monthly migraine days vs placebo1

SEE THE CLINICAL TRIAL RESULTS FOR AJOVY
Continue to AJOVY Dosing page

Only 4 injection days per year with quarterly dosing

dosing for AJOVY
Continue to AJOVY side effects page

Safety profile in clinical trials for AJOVY2

side effects for ajovy